Department of Nephrology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, 1 Fuhua Road, Futian District, Shenzhen, 518033, Guangdong, China.
Clin Exp Nephrol. 2024 Sep;28(9):925-931. doi: 10.1007/s10157-024-02498-3. Epub 2024 Apr 20.
Cardiovascular disease (CVD) represents the primary cause of mortality in patients afflicted with end-stage renal disease and undergoing peritoneal dialysis (PD) treatment. Galectin-3 (Gal-3), a molecule known to exhibit a correlation with CVD mortality garners considerable interest. The objective of this study was to explore the potential association between serum Gal-3 levels and other CVD risk factors among PD patients.
In this cross-sectional study, a total of 114 PD patients with a minimum of 3 months of PD treatment were enrolled. Serum Gal-3 levels were quantified using an enzyme-linked immunosorbent assay. The data of patients with Gal-3 levels higher and lower than 26.744 pg/ml were compared using Mann-Whitney U tests or t tests. Pearson's correlation or Spearman's correlation analysis and multivariate regression were used to assess the associations between the known risk factors for CVD and Gal-3.
In comparison to the inter-group baseline data, the low Gal-3 group exhibited a higher glomerular filtration rate (GFR). Gal-3 levels correlate positively with PD duration, B-type natriuretic peptide (BNP), growth differentiation factor 15 (GDF-15), interventricular septal thickness in diastolic (IVST), and left ventricular mass index (LVMI). Conversely, Gal-3 exhibited a negative correlation with albumin levels. Multivariate linear regression analysis demonstrated a positive correlation between Gal-3 levels and BNP, GDF-15, PD duration, IVST and LVMI. Gal-3 levels were negatively correlated with albumin levels.
Gal-3 was strongly associated with BNP, GDF-15, IVST and LVMI in patients undergoing PD treatment. Prospective studies should be carried out to determine whether Gal-3 can be a promising biomarker in predicting increased risk of adverse cardiovascular events in PD patients.
心血管疾病（CVD）是终末期肾病患者接受腹膜透析（PD）治疗后死亡的主要原因。半乳糖凝集素-3（Gal-3）是一种与 CVD 死亡率相关的分子，备受关注。本研究旨在探讨 PD 患者血清 Gal-3 水平与其他 CVD 危险因素之间的潜在关联。
本横断面研究纳入了 114 例 PD 患者，PD 治疗时间至少 3 个月。采用酶联免疫吸附试验定量检测血清 Gal-3 水平。使用 Mann-Whitney U 检验或 t 检验比较 Gal-3 水平高于和低于 26.744 pg/ml 的患者数据。采用 Pearson 相关或 Spearman 相关分析和多元回归分析评估 CVD 已知危险因素与 Gal-3 之间的关系。
与组间基线数据相比，低 Gal-3 组的肾小球滤过率（GFR）较高。Gal-3 水平与 PD 持续时间、B 型利钠肽（BNP）、生长分化因子 15（GDF-15）、舒张期室间隔厚度（IVST）和左心室质量指数（LVMI）呈正相关，与白蛋白水平呈负相关。多元线性回归分析显示，Gal-3 水平与 BNP、GDF-15、PD 持续时间、IVST 和 LVMI 呈正相关，与白蛋白水平呈负相关。
Gal-3 与接受 PD 治疗的患者的 BNP、GDF-15、IVST 和 LVMI 密切相关。应进行前瞻性研究，以确定 Gal-3 是否可以成为预测 PD 患者不良心血管事件风险增加的有前途的生物标志物。
